Correlation Engine 2.0
Clear Search sequence regions

  • absorb (3)
  • cohort (1)
  • death (2)
  • mace (2)
  • patients (6)
  • registry (4)
  • thrombosis (2)
  • vessel (3)
  • Sizes of these terms reflect their relevance to your search.

    To analyze procedural results and mid-term safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) used for percutaneous coronary intervention in a large all-comer cohort from the German-Austrian ABSORB Registry (GABI-R). A total of 3231 patients were included in this prospective, observational, multicentre study ( NCT02066623) of consecutive patients undergoing BVS implantation between November 2013 and January 2016. Endpoints were major adverse cardiac events (MACE, a composite endpoint of death, target vessel revascularization, and myocardial infarction) and target lesion failure (TLF), a composite endpoint of cardiac death, target vessel myocardial infaction, and target lesion revascularization). Scaffold thrombosis was a further endpoint. Of all patients, 51.5% presented with acute coronary syndrome. Pre-dilatation and post-dilatation were performed in 91.5% and 71.9% of patients. Procedural success was 98.9%. After 6 months, the incidence of MACE was 4.1% and of TLF 2.4%. The rate of target vessel MI was 1.5%, and target lesion revascularization was performed in 1.8%. Definite/ probable scaffold thrombosis was documented in 1.4% of patients. GABI-R, the largest registry to provide data regarding safety after BVS implantation in a real-world setting, reveals high procedural success and low 6-month event rates.


    Holger M Nef, Jens Wiebe, Johannes Kastner, Julinda Mehilli, Thomas Münzel, Christoph Naber, Till Neumann, Gert Richardt, Axel Schmermund, Jochen Wöhrle, Ralf Zahn, Thomas Riemer, Stephan Achenbach, Christian W Hamm. Everolimus-eluting Bioresorbable Scaffolds in Patients with Coronary Artery Disease: Results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2017 Aug 22

    PMID: 28829745

    View Full Text